Study details
Enrolling now
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
Bantam Pharmaceuticals
NCT IDNCT06792734ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
24
Study length
about 2.9 years
Ages
18+
Locations
1 site in TX
About this study
Researchers are testing a new treatment, BTM-3566, to see if it can be safely given to adults with relapsed or refractory mature b cell lymphomas. The trial will also determine how well this treatment works and what side effects occur at different doses.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BTM-3566
PhasePhase 1
Primary goalAdverse Event and dose-limiting toxicity event rates
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Adverse Event and dose-limiting toxicity event rates